Meta-analyses for Tocilizumab - COVID
March 30th, 2021
Data
| study | year | events_patients | n_patients | events_controls | n_controls |
|---|---|---|---|---|---|
| COVACTA | 2020-09-04 | 58 | 294 | 28 | 144 |
| EMPACTA | 2020-10-21 | 26 | 249 | 11 | 128 |
| CORIMUNO-TOCI 1 | 2020-10-21 | 7 | 63 | 8 | 67 |
| RCT-TCZ-COVID-19 | 2020-10-21 | 2 | 60 | 1 | 66 |
| BACC Bay Tocilizumab Trial | 2020-10-22 | 9 | 161 | 3 | 81 |
| TOCIBRAS | 2021-01-22 | 14 | 65 | 6 | 64 |
| RECOVERY | 2021-02-12 | 596 | 2022 | 694 | 2094 |
| REMAP-CAP | 2021-02-26 | 98 | 350 | 142 | 397 |
| COVINTOC | 2021-03-09 | 11 | 90 | 15 | 90 |
Pairwise meta-analysis for Tocilizumab - COVID
Cumulative Meta-analyses for Tocilizumab - COVID
